India: Role Of IPR In Forming Legal Strategies For Pharma Industry

Last Updated: 16 October 2015
Article by Pranav K. Mysore, Ravi Bhola and Shivakumar R

Pharmaceutical industry currently has an evolving IPR strategy requiring a better focus and approach in the coming era. This article chalks out the evolving role of IPR in framing legal strategies for pharmaceutical industry.

In the era of globalisation, there is a constant technological race especially in the field of pharmaceuticals to develop new/improvised drugs. Due to this, pharmaceutical companies are making huge investments on R&D and hence, it is imperative to protect the Intellectual Property (IP) associated therein and obtain returns by its commercialisation. Accordingly, it is no surprise that IP, particularly patents have become important in framing legal strategies for pharmaceutical companies, right from the commencement of research till the expiry of patents. Frequently, pharmaceutical companies strategise on procuring and enforcing their patents, however, such strategies are not focused on how to maintain their patents when challenged for validity. On the other hand, economic liberalisation has seeded a competitive market pressurising the competitors to come out with generic or biosimilar versions for which suitable strategies have to be formulated1.

The exclusive monopolistic rights over an invention granted to pharmaceutical companies under the existing Indian Patent Regime are affected by issues such as restrictions during procurement of patents, lack of presumption of validity, use of patents under "Bolar Provision" and so on.

Restrictions for procurement of patents come by way of issues relating to patentable inventions, lack of enablement and pre-grant opposition by third parties. It is pertinent to mention here that the recently proposed guidelines by Indian Patent Office for examining pharmaceutical applications recommend enablement for all the groups claimed under "Markush Structure". The guideline with respect to enablement for all the groups under "Markush Structure" is unique in the sense that other jurisdictions accept enablement for some of the groups while Indian Patent Office suggests enablement for all the groups. Though these guidelines have not come into force and there may be a debate on this aspect, it is still better to consider these guidelines while drafting the application.

In addition to lack of enablement, it is seen that presently most patent applications in the field of pharmaceuticals do not comply with requirements of "enhanced therapeutic efficacy" under section 3(d) of Indian Patents Act, 1970. Often, while filing application for patent on an invention, enhanced efficacy data is misconstrued as the activity data of the compound so claimed. Per contra, enhanced efficacy data would mean a comparative data demonstrating enhanced efficacy of the compound so claimed over closest known compounds. Such misinterpretation has resulted in rejection of several patent applications in India. Although other countries do not have such an express provision, they do conduct examination and raise objections under inventiveness as it is sometimes raised under section 3(d). Lack of enhanced efficacy data not only affects the patents from being granted by the patent offices, but also allows third party to file pre-grant opposition. Such rigorous process during prosecution and a right given to third party to oppose grant puts evergreening of patents under scrutiny.

Even if a third party loses out on filing a pre-grant opposition, options to invalidate a granted patent are available by way of post-grant opposition or revocation of patent. Yet again, these provisions act as a check on evergreening of patents amongst other legislative framework. On the other hand, patentee can institute infringement action against the infringer to protect and safeguard the interest in the patent, thus preventing anyone from practicing patentee's invention for commercial gains.

During proceedings such as opposition, revocation or infringement, the strategy lies in providing appropriate information that would support and strengthen the stand taken by concerned parties. For example: A patent is said to be infringed on the grounds that the patentee has monopoly over a particular compound A. The patentee identified that a third party is infringing the patent by selling salt Y of the compound A. It was found during proceedings that the patentee had filed another application for salt Y of the compound A which was abandoned later. The defendant argued that it is imperative from these facts that the plaintiff (patentee) themselves considered compound A and salt Y of compound A to be different from one another. Such being the case, the patent covering compound A cannot be said to be infringed by the defendants product - salt Y of compound A, even though the patent claims relate to pharmaceutically acceptable salts of compound A. The Hon'ble Delhi High Court held that the plaintiff ought to have shown the defendant's product remained equivalent to compound A to establish prima facie case of infringement2. The decision was appealed and the order is yet to be passed in this case. It appears that the case would have been in favour of the patentee if the activity of the compound A and its salt form Y was shown as equivalent. Even though such proof could be furnished at the appeal stage, the issue could have been resolved in the preliminary stage itself if it was proved. Another important factor to be considered based on this case is to decide on the need for filing independent patent applications for related subject-matter as such filings have a bearing on the parent application at a later date. One probable option that pharmaceutical companies can consider in such situation is to file a divisional application/patent of addition depending on case to case basis rather than filing an independent application for related subject-matter.

Having said the above, there are certain provisions in the law which allow third party to use patent granted to the patentee. One such provision relates to compulsory licensing, wherein any person interested may request for issuance of an involuntary licence to practice a granted patent, subject to certain conditions - meeting reasonable requirement of public such as accessibility and affordability, in addition to working of the patented invention in India. IPAB has held that the term "Worked" has a flexible meaning based on the specific facts3 . If the working of the invention is not feasible, the onus lies with the patentee to prove as to how the working was not feasible without merely making a statement to this extent.

Another provision under which a patent can be used by third party is "Bolar Provision" which is present in legislative framework of many countries. Bolar Provision is a specific enablement towards using the patent without authorisation of the patentee for the purpose of research, development and to obtain approval from regulatory authority. India has added one extra element to this Bolar Provision which enables a person to even sell the patented product. The legislative intent incorporating this element to the existing known Bolar Provision should not be misinterpreted to state that any person can sell/manufacture the drug on a commercial scale. It has to be interpreted in a manner which is necessary for procuring approvals from various quarters of the Government.

Hence, Indian Bolar Provision has to be interpreted to state that any person can use/manufacture/sell /import the patented drug solely for the purpose of research and development and for the purpose of procuring regulatory approvals. Any misuse of this provision would be construed as infringement and necessary action can be instituted by the patentee.

Generally, the regulations in obtaining approval under Bolar Provision or after the expiry of the patent is simpler for generic drugs compared to biosimilars owing to the differences in the process by which the patented drug and biosimilars are produced. Thus, it is necessary to furnish clinical trial data for biosimilar versions while seeking approval from a regulatory authority. Though the regulatory aspect is not binding on Indian Patent Provisions for approving a patented drug, pharmaceutical companies are bound by such provisions for not selling the approved drug for commercial purposes until the expiry of the patent owing to the issues of infringement. In conclusion, framing right legal strategies based on the provisions available within the Indian legal framework would help pharmaceutical companies in addressing issues relating to procurement, enforcement and commercialisation of patents. Such strategies would lessen the challenges even if one cannot avoid the issues completely.



2) Merck v/s Glenmark – CS (OS) 586/2013 –Delhi High Court – order dated 05-04-2013.

3) Bayer vs. NATCO – OA/35/2012/PT/MUM – IPAB – order dated 04/03/20138)

Originally published in Pharma Bio World - June 2014

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Singh & Associates
Vaish Associates Advocates
Intepat IP Services Pvt Ltd
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Singh & Associates
Vaish Associates Advocates
Intepat IP Services Pvt Ltd
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions